John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses his research on the disparities in the care of endometrial cancer.
John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses his research on the disparities in the care of endometrial cancer.
Transcript
What sort of disparities did your research uncover about the receipt of care for high-grade endometrial cancer?
High-grade endometrial cancer is sort of the atypical version of endometrial cancer. Endometrial cancer has doubled in incidence in the United States in the last 20 years. The reason for that is the obesity epidemic, by and large, but most of those people are cured. It's the people with the high-grade or so-called type 2 endometrial cancers that require something other than surgery and have a much higher relapse rate.
So, even though it's 5% of people being diagnosed, it accounts for more than half of people that die from endometrial cancer. It seems to be shifted in the minority and non-classic populations.
For example, black women are more at risk for fibroids. They're also more at risk for some of these type 2 or high-grade endometrial cancers. So it's looking at the different health disparities and you would think that if there is 100 people with the same diagnosis that they would be treated the same way, with one of these more aggressive type of tumors. But that's not the case. And so, there are certain ethnic groups or race groups that tend to be under-treated for some reason or another.
Sometimes it's related to their insurance status, sometimes it's related to different philosophy, but that's what we were trying to drill down into.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen